Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
450.50
+6.68 (1.51%)
At close: Jun 6, 2025, 4:00 PM
443.53
-6.97 (-1.55%)
After-hours: Jun 6, 2025, 6:58 PM EDT

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 24 professional analysts, the 12-month price target for Vertex Pharmaceuticals stock ranges from a low of $423 to a high of $583. The average analyst price target of $512.42 forecasts a 13.74% increase in the stock price over the next year.

Price Target: $512.42 (+13.74%)
Analyst Consensus: Buy
Target Low Average Median High
Price $423 $512.42 $520 $583
Change -6.10% +13.74% +15.43% +29.41%
* Price targets were last updated on May 6, 2025.

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25May '25Jun '25
Strong Buy 101010101010
Buy 655666
Hold 101010101111
Sell 000000
Strong Sell 100000
Total 272525262727

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
RBC Capital
RBC Capital
Hold
Maintains
$420$423
Hold Maintains $420$423 -6.10% May 6, 2025
Scotiabank
Scotiabank
Hold
Maintains
$450$442
Hold Maintains $450$442 -1.89% May 6, 2025
Morgan Stanley
Morgan Stanley
Hold
Maintains
$462$464
Hold Maintains $462$464 +3.00% May 6, 2025
JP Morgan
JP Morgan
Buy
Maintains
$512$515
Buy Maintains $512$515 +14.32% May 6, 2025
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
$535
Buy Reiterates $535 +18.76% May 6, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
12.18B
from 11.02B
Increased by 10.48%
Revenue Next Year
13.48B
from 12.18B
Increased by 10.69%
EPS This Year
18.27
from -2.08
EPS Next Year
20.89
from 18.27
Increased by 14.39%
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
6.21B7.57B8.93B9.87B11.02B12.18B13.48B14.69B
Revenue Growth
49.08%22.06%17.91%10.51%11.66%10.48%10.69%9.02%
EPS
10.299.0112.8213.89-2.0818.2720.8922.95
EPS Growth
128.16%-12.44%42.29%8.35%--14.39%9.84%
Forward PE
-----24.6621.5619.63
No. Analysts
-----373526
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 12.9B 15.7B 17.7B
Avg 12.2B 13.5B 14.7B
Low 11.5B 11.7B 11.6B

Revenue Growth

Revenue Growth 20252026202720282029
High
16.7%
29.0%
31.4%
Avg
10.5%
10.7%
9.0%
Low
4.5%
-3.9%
-14.0%

EPS Forecast

EPS 20252026202720282029
High 19.73 28.05 33.75
Avg 18.27 20.89 22.95
Low 16.52 17.36 18.02

EPS Growth

EPS Growth 20252026202720282029
High -
53.5%
61.5%
Avg -
14.4%
9.8%
Low -
-5.0%
-13.7%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.